A phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non‐small cell lung cancer

Background. Combination chemotherapy with conventional antiproliferative drugs is becoming the treatment of choice for patients with advanced non‐small cell lung cancer (NSCLC), a good performance status, and no major clinical contraindications. Lonidamine (LND), a new drug with an innovative mechanism of action, might potentiate anticancer activity, without increasing toxicity.

[1]  P. Duffey,et al.  The calculation of actual or received dose intensity: a comparison of published methods. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  A. Biggi,et al.  Detection of suspected primary lung cancer by scintigraphy with indium-111-anti-carcinoembryonic antigen monoclonal antibodies (type F023C5) , 1991, Journal of Nuclear Medicine.

[3]  F. Guidi,et al.  A randomized trial of alternating chemotherapy versus best supportive care in advanced non-small-cell lung cancer. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  G. Buccheri Chemotherapy and survival in non-small cell lung cancer. The old vexata questio. , 1991, Chest.

[5]  C. Haskell Chemotherapy and survival of patients with non-small cell lung cancer. A contrary view. , 1991, Chest.

[6]  E. Vokes,et al.  Chemotherapy for non-small cell lung cancer. The continuing challenge. , 1991, Chest.

[7]  R. Hatlevoll,et al.  Symptomatic treatment versus combination chemotherapy for patients with extensive non‐small cell lung cancer , 1991, Cancer.

[8]  J. von Pawel,et al.  Phase III trial with and without lonidamine in non-small cell lung cancer. , 1991, Seminars in oncology.

[9]  B. Teicher,et al.  Lonidamine as a modulator of alkylating agent activity in vitro and in vivo. , 1991, Cancer research.

[10]  F. Pannuti,et al.  A phase II study on lonidamine combined with cisplatin and etoposide in the treatment of advanced non-small cell bronchogenic carcinoma (NSCBC). , 1990, Journal of chemotherapy.

[11]  D. Ferrigno,et al.  Further evidence in favour of chemotherapy for inoperable non-small cell lung cancer☆ , 1990 .

[12]  CJ Williams,et al.  A randomised trial of cisplatin and vindesine versus supportive care only in advanced non-small cell lung cancer. , 1990, British Journal of Cancer.

[13]  M. De Gregorio,et al.  Phase II study of lonidamine in non-small cell lung cancer: final report. , 1990, British Journal of Cancer.

[14]  R. Figlin,et al.  Supportive care versus supportive care and combination chemotherapy in metastatic non‐small cell lung cancer. Does chemotherapy make a difference? , 1989, Cancer.

[15]  G. Giaccone,et al.  Lonidamine versus Polychemotherapy in Advanced Non-Small-Cell Lung Cancer. A Preliminary Analysis , 1989, Tumori.

[16]  A. Curcio,et al.  Continuation of chemotherapy versus supportive care alone in patients with inoperable non‐small cell lung cancer and stable disease after two or three cycles of MACC. Results of a randomized prospective study , 1989, Cancer.

[17]  M. Rinaldi,et al.  Chemotherapy/radiation therapy plus/minus lonidamine in the treatment of non-small cell lung cancer (limited disease): preliminary results. , 1988, Seminars in oncology.

[18]  R. Souhami,et al.  Chapter 1 The first international workshop on small cell lung cancer antigens , 1988 .

[19]  J L Pater,et al.  Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  B. Silvestrini,et al.  In vitro and in vivo potentiation by lonidamine of the antitumor effect of adriamycin. , 1986, Anticancer research.

[21]  M. Staquet,et al.  Randomized Trials in Cancer: A Critical Review by Sites , 1986 .

[22]  A. Alfieri,et al.  Potentiation of radiation effects on two murine tumors by lonidamine. , 1986, Cancer research.

[23]  J. Sculier,et al.  Progress in chemotherapy of non-small cell lung cancer. , 1984, European journal of cancer & clinical oncology.

[24]  Chahinian Ap Conventional agents in lung cancer. , 1984 .

[25]  B. Silvestrini,et al.  Effects of lonidamine alone or combined with hyperthermia in some experimental cell and tumour systems. , 1983, British Journal of Cancer.

[26]  M Lavandier,et al.  Benefits of polychemotherapy in advanced non‐small‐cell bronchogenic carcinoma , 1982, Cancer.

[27]  B. Silvestrini,et al.  Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. , 1981, Cancer research.

[28]  B. Silvestrini,et al.  Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. , 1981, Journal of the National Cancer Institute.

[29]  A. Teirstein,et al.  Chemotherapy for bronchogenic carcinoma. Methotrexate, doxorubicin, cyclophosphamide, and lomustine. , 1977, JAMA.

[30]  R. A. Green,et al.  Alkylating agents in bronchogenic carcinoma. , 1969, The American journal of medicine.

[31]  A. Curcio,et al.  Combination chemotherapy with methotrexate, adriamycin, cyclophosphamide and CCNU (MACC) for nonsmall cell lung cancer. 4-year experience with 92 patients. , 1989, Oncology.

[32]  G. Scagliotti,et al.  Chronic administration of lonidamine in untreated non-small cell lung cancer of stage III M0-1. , 1989, Chemotherapy.

[33]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[34]  Edwin Silverberg,et al.  Cancer statistics, 1988 , 1988, CA: a cancer journal for clinicians.

[35]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[36]  A. Floridi,et al.  Kinetics of inhibition of mitochondrial respiration by antineoplastic agent lonidamine , 1986 .

[37]  A. Chahinian Conventional agents in lung cancer. , 1984, Cancer treatment reports.

[38]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[39]  H. Hansen,et al.  Commentary: current status of chemotherapy for non-small cell lung cancer. , 1981, Cancer treatment reports.

[40]  T. E. Walsh Reporting results. , 1969, Archives of otolaryngology.

[41]  O. Auerbach Histological Typing Of Lung Tumors , 1968 .

[42]  D. Karnofsky The clinical evaluation of chemotherapeutic agents in cancer , 1949 .